XTRA:BAYNPharmaceuticals
Is Bayer (XTRA:BAYN) Still Undervalued After An 84% Run?
Bayer stock has delivered a strong 83.8% return over the past year, yet its current valuation checks still suggest the shares lean cheap rather than stretched.
Over the last 12 months, Bayer is up 83.8%. This puts fresh focus on whether the recent share price strength has already captured the main improvement in expectations.
Recent news around the consolidation of the U.S. glyphosate business into Ruveon and the clinical research alliance with leading U.S. medical institutions can support...